dicyclomine, doxylamine, pyridoxine drug combination
(AAYNMUXDBOPKCP-UHFFFAOYSA-N)
Structure
- SMILES
- OC(=O)CCC(=O)O.CN(CCOC(c1ccccn1)(c1ccccc1)C)C.OCc1c(CO)cnc(c1O)C.Cl
- Molecular Formula:
- C29H40ClN3O8
- Molecular Weight:
- 594.096
- Log P:
- 3.7413
- Hydrogen Bond Acceptor:
- 11
- Hydrogen Bond Donor:
- 6
- TPSA:
- 173.54
- CAS Number(s):
- 99007-20-2
Synonym(s)
1.
dicyclomine, doxylamine, pyridoxine drug combination
2.
Debendox
3.
Diclectin
4.
Diclegis
5.
bendectin
6.
dicyclomine - doxylamine - pyridoxine
7.
doxylamine succinate - pyridoxine hydrochloride
8.
doxylamine succinate, pyridoxine hydrochloride drug combination
9.
doxylamine, pyridoxine drug combination
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Somnolence | FAERS: 21 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 2 | Drug ineffective | FAERS: 10 | US FAERS | |
| 3 | Vomiting | FAERS: 9 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 4 | Headache | FAERS: 7 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 5 | Nausea | FAERS: 7 | US FAERS | |
| 6 | Rebound effect | FAERS: 6 | US FAERS | |
| 7 | Drug Dependence | FAERS: 5 | US FAERS | |
| 8 | Fatigue | FAERS: 5 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 9 | Anxiety | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 10 | Maternal exposure during pregnancy | FAERS: 4 | US FAERS | |
| 11 | Palpitations | FAERS: 4 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Dizziness | FAERS: 3 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 13 | Drug screen false positive | FAERS: 3 | US FAERS | |
| 14 | Intentional product misuse | FAERS: 3 | US FAERS | |
| 15 | Anger | FAERS: 2 | US FAERS | |
| 16 | Disease recurrence | FAERS: 2 | US FAERS | |
| 17 | Drug dose omission | FAERS: 2 | US FAERS | |
| 18 | Drug effect incomplete | FAERS: 2 | US FAERS | |
| 19 | Drug ineffective for unapproved indication | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 20 | Hypersensitivity | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 21 | Inappropriate schedule of drug administration | FAERS: 2 | US FAERS | |
| 22 | Maternal exposure timing unspecified | FAERS: 2 | US FAERS | |
| 23 | Retching | FAERS: 2 | US FAERS | |
| 24 | Therapeutic response unexpected | FAERS: 2 | US FAERS | |
| 25 | Urinary Retention | FAERS: 2 | US FAERS | |
| 26 | Accidental exposure to product by child | FAERS: 1 | US FAERS | |
| 27 | Agitation | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 28 | Asthenia | FAERS: 1 | US FAERS | |
| 29 | Chest discomfort | FAERS: 1 | US FAERS | |
| 30 | Choking | FAERS: 1 | US FAERS | |
| 31 | Constipation | FAERS: 1 | US FAERS | |
| 32 | Craniosynostosis | FAERS: 1 | US FAERS | |
| 33 | Dehydration | FAERS: 1 | US FAERS | |
| 34 | Delayed sleep phase | FAERS: 1 | US FAERS | |
| 35 | Disorientation | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 36 | Drug dispensing error | FAERS: 1 | US FAERS | |
| 37 | Drug effect delayed | FAERS: 1 | US FAERS | |
| 38 | Drug screen positive | FAERS: 1 | US FAERS | |
| 39 | Drug withdrawal syndrome | FAERS: 1 | US FAERS | |
| 40 | Dysuria | FAERS: 1 | US FAERS | |
| 41 | Expired product administered | FAERS: 1 | US FAERS | |
| 42 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 43 | Heparin-induced thrombocytopenia | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 44 | Hypoplastic Left Heart Syndrome | FAERS: 1 | US FAERS | |
| 45 | Malaise | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 46 | Middle insomnia | FAERS: 1 | US FAERS | |
| 47 | Mood swings | FAERS: 1 | US FAERS | |
| 48 | Mydriasis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 49 | Overdose | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 50 | Pain | FAERS: 1 | US FAERS | |
| 51 | Polydactyly | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 52 | Prescribed overdose | FAERS: 1 | US FAERS | |
| 53 | Prescribed underdose | FAERS: 1 | US FAERS | |
| 54 | Product dispensing error | FAERS: 1 | US FAERS | |
| 55 | Product quality issue | FAERS: 1 | US FAERS | |
| 56 | Product taste abnormal | FAERS: 1 | US FAERS | |
| 57 | Regurgitation | FAERS: 1 | US FAERS | |
| 58 | Restless Legs Syndrome | FAERS: 1 | US FAERS | |
| 59 | Tachycardia | FAERS: 1 | US FAERS | |
| 60 | Therapy change | FAERS: 1 | US FAERS | |
| 61 | Therapy non-responder | FAERS: 1 | US FAERS | |
| 62 | Thrombocytopenia | FAERS: 1 | US FAERS | |
| 63 | Tremor | FAERS: 1 | US FAERS | |
| 64 | Urine alcohol test positive | FAERS: 1 | US FAERS | |
| 65 | Urticaria | FAERS: 1 | US FAERS | |
| 66 | Uterine contractions during pregnancy | FAERS: 1 | US FAERS | |
| 67 | Uterine spasm | FAERS: 1 | US FAERS | |
| 68 | Weight decreased | FAERS: 1 | US FAERS | |
| 69 | Wrong technique in product usage process | FAERS: 1 | US FAERS | |
| 70 | Adjustment disorder with depressed mood | Canada Vigilance: 1 | Canada Vigilance | |
| 71 | Congenital osteodystrophy | Canada Vigilance: 1 | Canada Vigilance | |
| 72 | Diplopia | Canada Vigilance: 1 | Canada Vigilance | |
| 73 | Dry skin | Canada Vigilance: 1 | Canada Vigilance | |
| 74 | Hyperphagia | Canada Vigilance: 1 | Canada Vigilance | |
| 75 | Mental impairment | Canada Vigilance: 1 | Canada Vigilance | |
| 76 | Nervousness | Canada Vigilance: 1 | Canada Vigilance | |
| 77 | Optic Nerve Hypoplasia | Canada Vigilance: 1 | Canada Vigilance | |
| 78 | Phalangeal agenesis | Canada Vigilance: 1 | Canada Vigilance | |
| 79 | Photophobia | Canada Vigilance: 1 | Canada Vigilance | |
| 80 | Restlessness | Canada Vigilance: 1 | Canada Vigilance | |
| 81 | Swelling of eyelid | Canada Vigilance: 1 | Canada Vigilance | |
| 82 | Vertigo | Canada Vigilance: 1 | Canada Vigilance | |
| 83 | Visual Impairment | Canada Vigilance: 1 | Canada Vigilance | |
| 84 | Visual brightness | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.